Document is current

Article History

Received: 2 July 2021

Revised: 30 July 2021

Accepted: 6 August 2021

First Online: 15 August 2021

Declarations

:

: Dr. Koch received consulting fees and travel support from Biogen, Novartis, Roche, Sanofi Genzyme and EMD Serono. Dr. Mostert reports no disclosures. Dr. Repovic received consulting and/or speaking honoraria from Alexion, Biogen Idec, Celgene, Roche, Sanofi Genzyme, Viela and EMD Serono. Dr. Bowen received honoraria from serving on the scientific advisory board and speaker’s bureau of Biogen Idec, Celgene, EMD Serono, Genentech and Novartis. He has received research support from AbbVie Inc, Alexion, Alkermes, Biogen Idec, Celgene, Sanofi Genzyme, Genentech, Novartis and TG Therapeutics. Dr. Strijbis reports no disclosures. Prof. Uitdehaag received consultancy fees and/or research support from Biogen, Sanofi Genzyme, EMD Serono, Novartis, Roche and Teva. Prof. Cutter served on <b>Data and Safety Monitoring Boards:</b> Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Horizon Pharmaceuticals, Hisun Pharmaceuticals, Mapi Pharmaceuticals LTD, Merck, Merck/Pfizer, Opko Biologics, OncoImmune, Neurim, Novartis, Ophazyme, Sanofi-Aventis, Reata Pharmaceuticals, Teva Pharmaceuticals, VielaBio Inc, Vivus, NHLBI (Protocol Review Committee), NICHD (OPRU oversight committee). <b>Consulting or Advisory Boards:</b> Biodelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel Incorporated, Medimmune, Medday, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion/Cerexis Pharmaceuticals, Roche, TG Therapeutics. Dr. Cutter is employed by the University of Alabama at Birmingham and President of Pythagoras, Inc. a private consulting company located in Birmingham AL.

: All participants in INFORMS gave their written informed consent and the trial was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Details of the ethical approval for INFORMS are described in the original trial publication. Ethical approval for this analysis was sought from and granted by the The University of Calgary Conjoint Health Research Ethics Board.